FDA Fires Warning Letter To Sun Pharma; Says Corrections At Cranbury Site Inadequate
This article was originally published in PharmAsia News
MUMBAI - Sun Pharmaceuticals - India's largest company by market capitalization - has been issued a warning letter by U.S. FDA for significant violations of good manufacturing practices at its Cranbury-based manufacturing site
You may also be interested in...
MUMBAI - In a span of less than 15 months, Ranbaxy - now part of Japanese pharma Daiichi Sankyo - will see a second changing of the guard, as chief executive Atul Sobti steps down and hands over the reigns to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business. Sawhney's promotion to managing director is effective Aug. 20
MUMBAI - A group of shareholders of U.S.-based generic drug maker Caraco Pharmaceutical has taken the company to court alleging that it violated securities laws by "recklessly disregarding May 29, 2008 and June 25, 2009 that their public statements concerning Caraco's business, operations and prospects were materially false and misleading." One of India's top generic drug makers, Sun Pharma, owns a majority 76 percent equity stake in Caraco
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).